Wednesday, April 08, 2015 5:45:28 PM
In a report published Wednesday, MLV & Co analysts maintained a Buy rating for Halozyme Therapeutics, Inc (NASDAQ: HALO), with a price target of $20.
Following a meeting with the FDA in 1Q15, the company has now announced its plans to commence a global registration based Phase 3 pancreatic cancer study in 1Q16. The pivotal trial is to be conducted in patients with pancreatic tumors that have high levels of hyaluronan (HA), and regulatory approval could be based on either overall survival (OS) or progression free survival (PFS).
In the report MLV & Co noted, "We continue to expect overall survival (OS) data from the ongoing Phase 2 Study 202 assessing the addition of PEGPH20 to gemcitabine + Abraxane at ASCO…HALO also plans to file an investigational device exemption (IDE) for the accompanying diagnostic, which we expect to be validated in the Phase 3 trial."
Survival data from Study 202 could be announced this year. Halozyme Therapeutics had indicated that interim overall survival (OS) data was discussed with the FDA. "As of March 3, the OS data was still maturing, putting the median follow-up of Study 202 patients at ~8.5 months currently. Since OS was 8.5 months in the pivotal Abraxane + gemcitabine trial, we expect Study 202 OS data could be presented at the American Society for Clinical Oncology meeting in May/June," the analysts wrote.
By the end of this year, the company is expected to be able to complete enrollment for the 114-patient Stage 2 portion of Study 202, Phase 1b dose and tolerability results from the PRIMAL study of PEGPH20 + docetaxel in HA high second-line NSCLC, followed by the commencement of the Phase 2 portion of the trial, and initiation of a PD-1 inhibitor + PEGPH20 combination study in second-line NSCLC.
"Additionally, we anticipate initiation of PEGPH20 combination trials with small molecules, monoclonal antibodies, and immunotherapy agents in multiple tumor types," the report mentioned.
The analysts mentioned the upcoming catalysts as:
For PEGPH20
Preliminary Phase 1b/2 PRIMAL dose and tolerability data of PEGPH20 + docetaxel in HA high, second line NSCLC in 3Q15
Preliminary results from the NSCLC immunotherapy trial in 1Q16
Commencement of the pivotal trial in high HA pancreatic cancer patients in 1Q16
For UltraFast Insulin
Clarity on a regulatory pathway to pave the way for a potential partnership in 2015
Latest Ratings for HALO DateFirmActionFromTo
Mar 2015BMO CapitalMaintainsOutperform Jan 2015JP MorganMaintainsOverweight Dec 2014MLV & Co. Initiates Coverage onBuy
View More Analyst Ratings for HALO
View the Latest Analyst Ratings
Recent HALO News
- Mahesh Krishnan Elected to Halozyme's Board of Directors • PR Newswire (US) • 04/25/2024 08:45:00 PM
- Halozyme to Report First Quarter 2024 Financial and Operating Results • PR Newswire (US) • 04/23/2024 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2024 09:13:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 11:49:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 09:07:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:05:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:01:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2024 09:08:09 PM
- Halozyme to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/27/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:59:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:55:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:53:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:49:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2024 09:07:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:03:54 PM
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 02/20/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:47:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:41:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:39:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:18:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:15:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:12:56 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 11:19:50 AM
- Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results • PR Newswire (US) • 02/08/2024 09:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM